INTELLIA THERAPEUTICS

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

25 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

20 Nov 2024 08:51:21 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 Nov 2024 09:10:43 By NetDania Notify

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

16 Nov 2024 09:16:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 Oct 2024 08:45:01 By NetDania Notify

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

31 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

30 Oct 2024 08:45:22 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

29 Oct 2024 10:48:28 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 Oct 2024 08:46:04 By NetDania Notify

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 Oct 2024 07:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 Oct 2024 08:45:05 By NetDania Notify

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 Oct 2024 09:23:57 By NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 Oct 2024 08:45:08 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 Oct 2024 08:45:32 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 Oct 2024 12:25:49 By NetDania Notify